LYNGE, DENMARK — WS Audiology (WSA), the parent company of hearing aid brands Signia and Widex, reported 2% organic revenue growth for its 2025/26 financial year, with improved profitability despite slower sales through its wholesale hearing aid business.
The company generated €2.54 billion (~$2.79 billion) in revenue during the 12 months ending September 30, 2026. Although underlying sales increased 2% after adjusting for factors such as currency fluctuations, total reported revenue declined slightly compared with the previous year.
WSA’s hearing care retail, managed care, and online businesses performed particularly well, while sales through its wholesale division were affected by the timing of new hearing aid introductions.
The company also highlighted the recent launches of Signia MaX and Widex Allure AI, two hearing aid platforms incorporating artificial intelligence to address challenging listening situations.
Hearing Care Retail and Managed Care Businesses Lead Growth
WSA reported 7% growth across its consumer-facing businesses, which include hearing care clinics, managed care services, and online operations.
By comparison, its wholesale business, which supplies hearing aids through professional distribution channels, experienced a 3% decline in underlying sales.
The company attributed the slower wholesale performance partly to the timing of its product launches, noting that sales began to improve toward the end of the financial year.
In the Americas, WSA reported 3% growth, while sales in Europe, the Middle East, Africa, and the Asia-Pacific region remained relatively unchanged.
Despite the uneven sales performance, WSA improved profitability. Its earnings before interest, taxes, depreciation, and amortization (EBITDA), excluding special items, increased to €473 million (~$520 million), up from €456 million (~$502 million) the previous year.
This measure reflects earnings from the company’s operations before certain financial and accounting expenses. WSA’s operating profit margin on that basis improved to 18.7%, up from 17.7% a year earlier.
“In the financial year 2025/26, we remained disciplined in executing our strategy and advancing innovation in personalized hearing care, and on driving profitability,” said Jan Mäkelä, CEO of WSA. “We delivered 2% organic revenue growth and improved the profit margin in line with our guidance. Our consumer-facing businesses performed strongly, while the timing of product launches impacted our wholesale business.”
New Signia and Widex Hearing Aids Highlight Technology Developments
WSA pointed to recent hearing aid launches as an important part of its strategy for the coming year, particularly new artificial intelligence capabilities introduced across its Signia and Widex brands.
The Signia MaX platform incorporates four deep neural networks (DNNs), which the company says work together to support speech understanding and listening comfort in complex acoustic environments.
The technology is designed to help hearing aid wearers navigate challenging listening situations, including environments with competing conversations and background noise.
WSA also highlighted the Widex Allure AI platform, which introduces Clarity Boost, an on-demand AI-powered feature intended to provide additional speech clarity when listening conditions become difficult.
Rather than continuously applying AI processing, Clarity Boost allows users to activate additional assistance when needed, while maintaining Widex’s emphasis on natural sound quality during everyday listening.
Together, the two platforms demonstrate WSA’s different approaches to personalized hearing technology across its major brands.
“At WSA, we believe that better hearing starts with recognizing that no two people hear the world in the same way,” Mäkelä said. “Understanding individual sound preferences opens up a new dimension in personalized hearing care.”
The company expects its new products, along with additional hearing aid styles and configurations, to support sales in the coming financial year.
Sales Improve Toward the End of the Year
WSA reported stronger results during the final three months of its financial year, suggesting that sales momentum was improving as newer products entered the market.
Revenue for the July–September quarter reached €654 million (~$719 million), representing 4% underlying growth compared with a 1% decline during the same period a year earlier.
Consumer-facing businesses grew 8% during the quarter, while wholesale hearing aid sales remained essentially unchanged.
The Americas recorded 5% growth, followed by Europe, the Middle East, and Africa at 3%, and Asia-Pacific at 1%.
Quarterly EBITDA, excluding special items, reached €126 million (~$139 million), with a modest improvement in profitability compared with the previous year.
Loss of Major U.S. Managed Care Contract Will Affect 2027 Results
Looking ahead, WSA expects a more challenging financial year, primarily because a major U.S. managed care customer will not renew its contract when the agreement expires on January 1, 2027.
The company estimates that losing the contract will reduce its overall revenue growth by approximately five percentage points during the 2026/27 financial year.
For example, if the company’s other businesses were to generate 5% growth, the loss of the contract could effectively offset that increase.
WSA also expects the contract loss to reduce its profitability, although cost-saving measures and other operational improvements are expected to offset part of the impact.
As a result, the company forecasts revenue growth ranging from a 2% decline to a 2% increase for the coming year.
Without the impact of the expiring contract, WSA expects its business to grow at least as quickly as the overall hearing aid market, which it anticipates will see approximately 3% to 4% growth in hearing aid unit sales.
“Our outlook for 2026/27 is impacted by the non-renewal of a large US managed care contract, as previously announced,” Mäkelä said. “Excluding this impact, we expect revenue to grow in line with or above the market, with continued improvement in profitability.”
The company said it will continue focusing on new hearing technology, operational efficiency, and expansion of its product portfolio as it adjusts to the change in its U.S. managed care business.
For hearing care professionals, the results illustrate how hearing aid manufacturers are influenced not only by new technology and consumer demand, but also by distribution relationships, managed care agreements, and the timing of product introductions.
With Signia MaX and Widex Allure AI now entering the market, WSA’s performance over the coming year will offer further insight into how these newer technologies contribute to the company’s hearing aid business.
The company’s full annual results are available through WSA’s investor reports.
Source: WSA







